查詢結果分析
來源資料
相關文獻
- Discontinuation and Adverse Events or Events of Etanercept Treatment in Patients with Rheumatoid Arthritis
- The Risk of Serious Infections in Patients with Rheumatoid Arthritis Treated with Different Tumor Necrosis Factor α Inhibitors
- 膝關節置換術前使用免疫抑制劑與感染的關係
- 抗腫瘤壞死因子藥物與類風濕性關節炎
- 抗腫瘤壞死因子製劑(Anti-TNF)
- 生物製劑在類風濕性關節炎之治療
- Cefmetazole對腹腔感染的臨床評估
- Taiwan Experience with Etanercept in Juvenile Rheumatoid Arthritis
- 免疫生物製劑對結核病、B型與C型病毒肝炎活化之影響
- Infective Endocarditis with Septic Shock in a Rheumatoid Arthritis Patient Being Treated with Etanercept
頁籤選單縮合
題名 | The Risk of Serious Infections in Patients with Rheumatoid Arthritis Treated with Different Tumor Necrosis Factor α Inhibitors=類風濕性關節炎患者經不同抗腫瘤壞死因子藥物治療後比較其產生嚴重性感染的風險 |
---|---|
作者 | 鄭硯寧; 陳一銘; 謝祖怡; 陳怡行; 陳得源; | 書刊名 | 中華民國風濕病雜誌 |
卷期 | 27:2 2013.12[民102.12] |
頁次 | 頁67-74 |
分類號 | 415.695 |
關鍵詞 | 類風濕性關節炎; 抗腫瘤壞死因子; 感染; Rheumatoid arthritis; Tumor necrosis factor-α; Infection; |
語文 | 英文(English) |
中文摘要 | 評估台中榮總於2007至2012年間使用恩博或復邁治療類風濕性關節炎的患者其產生嚴重性感染的風險是否有所差異。方法:回溯性收集使用恩博或復邁的類風濕性關節炎患者其基本資料、臨床表徵、檢查結果,以及紀錄恩博或復邁治療過程中產生的嚴重性感染。計算發生嚴重性感染的機率,以及分析是否有獨立的危險因子。結果:共595位病人被納入,其中319位(佔54%)使用恩博,另外276位(佔46%)使用復邁。整體發生嚴重性感染的機會是每百人年6.45,恩博為每百人年5.05,而復邁為每百人年8.28。經統計分析相對於恩博而言使用復邁確實有顯著較高的嚴重性感染率。此外,若使用抗腫瘤壞死因子藥物當時的年紀較大,或是原本有慢性肺部疾病的患者,也有較高的機會會發生嚴重性感染。結論:本研究族群中使用復邁比恩博有更高的嚴重性感染的風險。 |
英文摘要 | To evaluate the risk of serious infection in patients with rheumatoid arthritis (RA) treated with etanercept or adalimumab between 2007 and 2012 in a single medical center. Methods: We retrospectively collected the demographic data, clinical characteristics, laboratory findings, and all episodes of serious infection during anti-tumor necrosis factor (TNF)-α therapy. The incidence rate was calculated from the observed number of serious infections and patient-years of follow-up. Univariate and multivariate logistic regression analyses were made to identify the independent predictors of serious infection. Results: A total of 595 patients were included in the analyses: 319 (54%) treated with etanercept and 276 (46%) treated with adalimumab. The overall incidence rate was 6.45/100 patient-years: 5.05/100 patient-years for etanercept and 8.28/100 patient-years for adalimumab. The risk of serious infection was significantly higher in adalimumab than in etanercept (adjusted OR: 2.01, 95% CI: 1.15-3.49, p=0.014). Advanced age at the start of TNF-α inhibitor therapy and chronic pulmonary diseases were associated with significantly higher independent risks for serious infection. Conclusion: The risk of serious infection in RA patients treated with adalimumab was significantly higher than that in RA patients treated with etanercept in this cohort. |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。